Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals is conducting a Phase 1b clinical study titled ‘Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma.’ The study aims to evaluate the safety and optimal dosage of linvoseltamab when combined with other cancer treatments for patients with multiple myeloma that is resistant to standard therapies. This research is significant as it explores new treatment combinations for a challenging condition.
The study is testing linvoseltamab, an experimental drug, in combination with various other cancer treatments such as Daratumumab, Carfilzomib, and Lenalidomide, among others. Linvoseltamab is administered via intravenous infusion, and the combinations aim to enhance treatment efficacy for multiple myeloma.
The study follows a non-randomized, sequential intervention model with no masking, focusing primarily on treatment. This design allows researchers to assess the effects of linvoseltamab in combination with other drugs in a structured manner.
The study began on November 18, 2021, and is currently recruiting participants. The last update was submitted on August 27, 2025. These dates are crucial as they indicate the study’s progress and ongoing nature.
This clinical update could positively impact Regeneron’s stock performance by showcasing their commitment to innovative cancer treatments. It may also influence investor sentiment positively, given the potential for new therapeutic options in a competitive oncology market.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.